Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Machaon who wrote (19102)	4/17/1998 7:50:00 AM
From: Henry Niman	Read Replies (1) of 32384

Another compound that appears to be ready for IND filing is the androgen antagonist, LGD1331. In the table it is shown to be as advanced as TSE424 and AHP recently entered it into the clinic. The anti-androgen targets very large markets including prostate cancer, BPH, and hursutism. Early reports by Bear Stearns' David Molowa had suggested that LGND would develop the prostate cancer indication and license out BPH and hursutism. The table suggests that the time line for some sort of announcement(s) is very short. The annual report also seems to be talking more about Men's Health in addition to Women's Health as niche areas for LGND.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next